Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.
Related
Luke Sykora,
Stanford University
Starting Up in a Downturn
An Entrepreneurial Thought Leaders mini-guide for aspiring founders facing a troubled economy.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
